JP Morgan Chase
ZVRA icon

JP Morgan Chase’s Zevra Therapeutics ZVRA Stock Holding History

JP Morgan Chase’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-75,000
Closed -$962K – 6865
2021
Q2 		$962K Hold
75,000
– – ﹤0.01% 4320
2021
Q1 		$690K Buy
+75,000
New +$655K ﹤0.01% 4475

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's ZVRA Position: Q2 2026 in Review

JP Morgan Chase reduced its Zevra Therapeutics (ZVRA) stake by 4.8% in Q2 2026, selling an estimated $200K and leaving 360,925 shares worth $5.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3444.

JP Morgan Chase first reported a position in ZVRA in Q2 2015 and has held it in 31 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • JP Morgan Chase held 360,925 shares of Zevra Therapeutics worth $5.06M as of Q2 2026.
  • JP Morgan Chase sold 18,007 Zevra Therapeutics shares in Q2 2026, an estimated $200K.
  • Zevra Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3444 holding.
  • JP Morgan Chase first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 31 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.